Quality of life versus prolongation of life in patients treated with chemotherapy in advanced colorectal cancer: A review of randomized controlled clinical trials

被引：23

作者：

de Kort, SJ

Willemse, PHB

Habraken, JM

de Haes, HCJM

Willems, DL

Richel, DJ

机构：

[1] Univ Amsterdam, Acad Med Ctr, Dept Gen Practice, NL-1100 DD Amsterdam, Netherlands

[2] Acad Hosp Groningen, Dept Internal Med, Groningen, Netherlands

[3] Univ Amsterdam, Acad Med Ctr, Dept Psychol Med, Amsterdam, Netherlands

[4] Univ Amsterdam, Acad Med Ctr, Dept Internal Med, Amsterdam, Netherlands

来源：

EUROPEAN JOURNAL OF CANCER | 2006年 / 42卷 / 07期

关键词：

review; quality of life; toxicity; survival gain; chemotherapy; advanced colorectal cancer;

D O I：

10.1016/j.ejca.2005.10.026

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Oncologists disagree if chemotherapy in advanced cancer can improve quality of life (QoL), to prolong duration of life, or both. The objective of this study was to clarify the main treatment intention of palliative chemotherapy (PCT): the prolongation of life (PoL); or QoL. Randomized controlled clinical trials of PCT in advanced colorectal cancer that included HRQoL assessment were selected from PubMed and reviewed. Authors' conclusions were based on both PoL- and QoL-related outcomes. However, if PoL and QoL outcomes of the experimental arm were opposite, which was the case in 13 out of 28 trials, the authors generally based their conclusion on PoL outcomes. Authors' conclusions focused mainly on Pol.-related outcomes, while QoL-related outcomes were of overriding importance in only 1/28 case. QoL can therefore not be considered as the main outcome of PCT. The review shows that in the context of chemotherapy in advanced colorectal cancer, 'palliative' refers to a life-prolonging intention, whereas within palliative care it refers to an improvement in QoL. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：835 / 845

页数：11

共 39 条

[1] QUALITY-OF-LIFE AND SURVIVAL WITH CONTINUOUS HEPATIC-ARTERY FLOXURIDINE INFUSION FOR COLORECTAL LIVER METASTASES [J].

ALLENMERSH, TG ;

EARLAM, S ;

FORDY, C ;

ABRAMS, K ;

HOUGHTON, J .

LANCET, 1994, 344 (8932) :1255-1260

[2] A double-blind placebo-controlled randomized phase III trial of 5-fluorouracil and leucovorin, plus or minus trimetrexate, in previously untreated patients with advanced colorectal cancer [J].

Blanke, CD ;

Shultz, J ;

Cox, J ;

Modiano, M ;

Isaacs, R ;

Kasimis, B ;

Schilsky, R ;

Fleagle, J ;

Moore, M ;

Kemeny, N ;

Carlin, D ;

Hammershaimb, L ;

Haller, D .

ANNALS OF ONCOLOGY, 2002, 13 (01) :87-91

[3]

Buyse M, 2005, J CLIN ONCOL, V23, p249S

[4] Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer [J].

Carmichael, J ;

Popiela, T ;

Radstone, D ;

Falk, S ;

Borner, M ;

Oza, A ;

Skovsgaard, T ;

Munier, S ;

Martin, C .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) :3617-3627

[5] A RANDOMIZED STUDY OF BOLUS FLUOROURACIL PLUS FOLINIC ACID VERSUS 21-DAY FLUOROURACIL INFUSION ALONE OR IN ASSOCIATION WITH CYCLOPHOSPHAMIDE AND MITOMYCIN-C IN ADVANCED COLORECTAL-CARCINOMA [J].

CAUDRY, M ;

BONNEL, C ;

FLOQUET, A ;

MARSAULT, C ;

QUETIN, P ;

PUJOL, J ;

MATON, O ;

DUJOLS, JP ;

CAUDRY, Y ;

SKAWINSKI, P ;

CARENCO, J ;

MOKHTARI, F ;

CELERIER, D ;

QUINTON, A ;

DEMEAUX, H ;

MAIRE, JP .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1995, 18 (02) :118-125

[6] Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer [J].

Cocconi, G ;

Cunningham, D ;

Van Cutsem, E ;

Francois, E ;

Gustavsson, B ;

van Hazel, G ;

Kerr, D ;

Possinger, K ;

Hietschold, SM .

JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (09) :2943-2952

[7] Biweekly irinotecan or raltitrexed plus 6S-leucovorin and bolus 5-fluorouracil in advanced colorectal carcinoma:: A Southern Italy Cooperative Oncology Group phase II-III randomized trial [J].

Comella, P ;

De Vita, F ;

Mancarella, S ;

De Lucia, L ;

Biglietto, M ;

Casaretti, R ;

Farris, A ;

Ianniello, GP ;

Lorusso, V ;

Avallone, A ;

Cartenì, G ;

Leo, S ;

Catalano, G ;

De Lena, M ;

Comella, G .

ANNALS OF ONCOLOGY, 2000, 11 (10) :1323-1333

[8] 'Tomudex' (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia [J].

Cunningham, D ;

Zalcberg, JR ;

Rath, U ;

Olver, I ;

VanCutsem, E ;

Svensson, C ;

Seitz, JF ;

Harper, P ;

Kerr, D ;

PerezManga, G ;

Azab, M ;

Seymour, L ;

Lowery, K ;

Ackland, SP ;

Basser, RL ;

Clarke, SJ ;

Goldstein, D ;

Green, MD ;

Grygiel, JJ ;

McKendrick, JJ ;

Millward, MJ ;

Olver, IN ;

Tattersall, MHN ;

Thomson, DB ;

Jakesz, R ;

Buset, M ;

Tueni, EA ;

VanCutsem, EJD ;

Bauer, J ;

Beska, F ;

Adenis, A ;

Brunet, R ;

Francois, E ;

Paillot, B ;

Rougier, P ;

Fink, UFW ;

Knuth, KRA ;

Koenig, HJ ;

Bohme, MWJ ;

Wander, HE ;

Amadori, D ;

Frassineti, L ;

Cocconi, G ;

Passalacqua, R ;

Frigerio, F ;

Barni, S ;

Luporini, G ;

Labianca, R ;

Marini, G ;

Zaniboni, A .

EUROPEAN JOURNAL OF CANCER, 1995, 31A (12) :1945-1954

[9] Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer [J].

Cunningham, D ;

Pyrhönen, S ;

James, RD ;

Punt, CJA ;

Hickish, TF ;

Heikkila, R ;

Johannesen, TB ;

Starkhammar, H ;

Topham, CA ;

Awad, L ;

Jacques, C ;

Herait, P .

LANCET, 1998, 352 (9138) :1413-1418

[10] Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer [J].

de Gramont, A ;

Figer, A ;

Seymour, M ;

Homerin, M ;

Hmissi, A ;

Cassidy, J ;

Boni, C ;

Cortes-Funes, H ;

Cervantes, A ;

Freyer, G ;

Papamichael, D ;

Le Bail, N ;

Louvet, C ;

Hendler, D ;

de Braud, F ;

Wilson, C ;

Morvan, F ;

Bonetti, A .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (16) :2938-2947

← 1 2 3 4 →